

DCGI approves SII's cervical cancer vaccine

16 July 2022 | News

Aadar C Poonawala, CEO and Owner, SII thanks DCGI and MoH&FW



Drugs Controller General of India (DCGI) granted market authorisation to Serum Institute of India (SII) to manufacture indigenously-developed India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. DCGI's approval comes following recommendation by the Subject Expert Committee (SEC) on COVID-19 of the CDSCO.

Aadar C Poonawala, CEO and Owner, SII, in a tweet stated, "For the first time there will be an Indian HPV vaccine to treat cervical cancer in women that is both affordable and accessible. We look forward to launching it later this year and we thank the DCGI and MoH&FW for the same.